Evidence map›Paper›PMID 35307777›Full record

ArticleNeurochemical research2022

Development and Validation of Arc Nanobodies: New Tools for Probing Arc Dynamics and Function.

Yuta Ishizuka, Tadiwos F Mergiya, Rodolfo Baldinotti, Ju Xu, Erik I Hallin, Sigurbjörn Markússon, Petri Kursula, Clive R Bramham

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in Neurochemical research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Applications of nanobodies in brain diseases.Frontiers in immunology · 2022
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 3 countries.

Yuta IshizukaDepartment of Biomedicine, University of Bergen, Jonas Lies 91, 5009, Bergen, Norway. yuta.ishizuka@med.kawasaki-m.ac.jp.ORCID http://orcid.org/0000-0002-2036-902X
Tadiwos F MergiyaDepartment of Biomedicine, University of Bergen, Jonas Lies 91, 5009, Bergen, Norway.
Rodolfo BaldinottiDepartment of Biomedicine, University of Bergen, Jonas Lies 91, 5009, Bergen, Norway.ORCID http://orcid.org/0000-0002-8918-1973
Ju XuDepartment of Biomedicine, University of Bergen, Jonas Lies 91, 5009, Bergen, Norway.
Erik I HallinDepartment of Biomedicine, University of Bergen, Jonas Lies 91, 5009, Bergen, Norway.
Sigurbjörn MarkússonDepartment of Biomedicine, University of Bergen, Jonas Lies 91, 5009, Bergen, Norway.ORCID http://orcid.org/0000-0003-4364-2997
Petri KursulaDepartment of Biomedicine, University of Bergen, Jonas Lies 91, 5009, Bergen, Norway.ORCID http://orcid.org/0000-0001-8529-3751
Clive R BramhamDepartment of Biomedicine, University of Bergen, Jonas Lies 91, 5009, Bergen, Norway. clive.bramham@uib.no.ORCID http://orcid.org/0000-0001-5958-7115
University of Bergen · NOKawasaki Medical School · JP

Funding

Norges Forskningsråd 249951Trond Mohn Foundation TMS3032TMT04
6 · The paper itself

Abstract

Activity-regulated cytoskeleton-associated (Arc) protein plays key roles in long-term synaptic plasticity, memory, and cognitive flexibility. However, an integral understanding of Arc mechanisms is lacking. Arc is proposed to function as an interaction hub in neuronal dendrites and the nucleus, yet Arc can also form retrovirus-like capsids with proposed roles in intercellular communication. Here, we sought to develop anti-Arc nanobodies (ArcNbs) as new tools for probing Arc dynamics and function. Six ArcNbs representing different clonal lines were selected from immunized alpaca. Immunoblotting with recombinant ArcNbs fused to a small ALFA-epitope tag demonstrated binding to recombinant Arc as well as endogenous Arc from rat cortical tissue. ALFA-tagged ArcNb also provided efficient immunoprecipitation of stimulus-induced Arc after carbachol-treatment of SH-SY5Y neuroblastoma cells and induction of long-term potentiation in the rat dentate gyrus in vivo. Epitope mapping showed that all Nbs recognize the Arc C-terminal region containing the retroviral Gag capsid homology domain, comprised of tandem N- and C-lobes. ArcNbs E5 and H11 selectively bound the N-lobe, which harbors a peptide ligand binding pocket specific to mammals. Four additional ArcNbs bound the region containing the C-lobe and C-terminal tail. For use as genetically encoded fluorescent intrabodies, we show that ArcNbs fused to mScarlet-I are uniformly expressed, without aggregation, in the cytoplasm and nucleus of HEK293FT cells. Finally, mScarlet-I-ArcNb H11 expressed as intrabody selectively bound the N-lobe and enabled co-immunoprecipitation of full-length intracellular Arc. ArcNbs are versatile tools for live-cell labeling and purification of Arc, and interrogation of Arc capsid domain specific functions.

Indexed as

NeuroblastomaSingle-Domain AntibodiesAnimalsCytoskeletal ProteinsHumansLong-Term PotentiationMammalsNerve Tissue ProteinsNeuronal PlasticityRatsCytoskeletal ProteinsNerve Tissue ProteinsSingle-Domain AntibodiesArcChromobodyC-lobeCo-immunoprecipitationIntrabodyNanobodyN-lobe

Identifiers

PMID35307777
PMCPMC9463278
OpenAlexW4220656916

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.